{"id":"opn-375","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By activating 5-HT4 receptors in the gastrointestinal tract, OPN-375 promotes coordinated muscle contractions that propel food through the stomach more efficiently. This mechanism addresses the underlying pathophysiology of gastroparesis, a condition characterized by delayed gastric emptying and associated symptoms such as nausea, vomiting, and early satiety.","oneSentence":"OPN-375 is a selective serotonin 5-HT4 receptor agonist that enhances gastric motility and accelerates gastric emptying.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:24:40.577Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastroparesis (diabetic and idiopathic)"}]},"trialDetails":[{"nctId":"NCT03747458","phase":"PHASE3","title":"OPN-375 Efficacy and Safety in Adolescents With Bilateral Nasal Polyps","status":"RECRUITING","sponsor":"Optinose US Inc.","startDate":"2018-12-31","conditions":"Bilateral Nasal Polyposis","enrollment":72},{"nctId":"NCT06850805","phase":"PHASE3","title":"Efficacy and Safety of 186 mcg of OPN-375 Nasal Spray Twice a Day (BID) in Adolescents With Chronic Rhinosinusitis Without Nasal Polyps","status":"RECRUITING","sponsor":"Optinose US Inc.","startDate":"2025-07-28","conditions":"Chronic Rhinosinusitis Without Nasal Polyps","enrollment":84},{"nctId":"NCT03781804","phase":"PHASE3","title":"Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis With or Without the Presence of Nasal Polyps","status":"COMPLETED","sponsor":"Optinose US Inc.","startDate":"2018-11-27","conditions":"Chronic Rhinosinusitis","enrollment":332},{"nctId":"NCT03960580","phase":"PHASE3","title":"Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis Without the Presence of Nasal Polyps","status":"COMPLETED","sponsor":"Optinose US Inc.","startDate":"2019-06-06","conditions":"Chronic Rhinosinusitis","enrollment":223},{"nctId":"NCT03591068","phase":"PHASE3","title":"Efficacy & Safety of OPN-375 Adults With Bilateral Nasal Polyps Using Nasoendoscopic Video","status":"COMPLETED","sponsor":"Optinose US Inc.","startDate":"2018-06-07","conditions":"Nasal Polyposis","enrollment":11},{"nctId":"NCT01622569","phase":"PHASE3","title":"Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi Directional Device in Subjects With Bilateral Nasal Polyposis Followed by an 8-Week Open-Label Extension Phase to Assess Safety","status":"COMPLETED","sponsor":"Optinose US Inc.","startDate":"2013-11-19","conditions":"Bilateral Nasal Polyposis","enrollment":323},{"nctId":"NCT01624662","phase":"PHASE3","title":"Efficacy and Safety Study of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Using a Novel Bi-directional Device","status":"COMPLETED","sponsor":"Optinose US Inc.","startDate":"2013-10-30","conditions":"Bilateral Nasal Polyposis","enrollment":323},{"nctId":"NCT01623310","phase":"PHASE3","title":"12-Month OL Intranasal Fluticasone Propionate BID Using OptiNose Device","status":"COMPLETED","sponsor":"Optinose US Inc.","startDate":"2013-09","conditions":"Nasal Polyps","enrollment":223}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"OPN-375","genericName":"OPN-375","companyName":"Optinose US Inc.","companyId":"optinose-us-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"OPN-375 is a selective serotonin 5-HT4 receptor agonist that enhances gastric motility and accelerates gastric emptying. Used for Gastroparesis (diabetic and idiopathic).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}